GlassScriptPhysician profile
Sarah Cubas
NPI 1639803604
$1,682.63
in general payments reported to CMS, 2019-2025
14 companies · $260 in 2025
The $260 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $424 · 2023: $604 · 2024: $395 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,258.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $465.90 | 2022-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $307.45 | 2022-2024 | Farxiga, Lokelma |
| Novartis Pharmaceuticals Corporation | $162.99 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $146.33 | 2022-2025 | Velphoro, Velphoro |
| Horizon Therapeutics Plc | $120.09 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $91.60 | 2023-2024 | |
| Akebia Therapeutics INC | $73.17 | 2022 | |
| Travere Therapeutics, INC. | $70.41 | 2024-2025 | |
| Lilly USA, LLC | $67.21 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $53.47 | 2022-2023 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $46.46 | 2022-2025 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.07 | 2025 | Jardiance |
| Nxstage Medical, INC. | $24.37 | 2022 | |
| Ardelyx, INC. | $20.11 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cubas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.